Magnificat High School, Westlake, Ohio, USA.
Pancreatology. 2009;9(6):764-9. doi: 10.1159/000201304. Epub 2010 Jan 21.
Numerous publications from academic centers suggest that magnetic resonance cholangiopancreatography (MRCP) can diagnose early chronic pancreatitis (CP) and assess pancreatic secretory reserve/function. However, the rigorous composite interpretation methods and quantitative secretory dynamics reported in these studies are not routinely measured in clinical practice. Therefore, the utility of routine MRCP reports in the clinical setting is unknown.
Cross-sectional study of patients referred to a tertiary center who underwent both MRCP and endoscopic pancreas function testing (ePFT) for assessment of chronic pancreatitis and abdominal pain.
To compare MRCP and sMRCP reports to a reference standard pancreas function test for diagnosis of chronic pancreatitis.
Source population: patients seen within a pancreas clinic at a tertiary referral center. MRCP and sMRCP reports were reviewed to record pancreas duct (dilation, side-branch changes), parenchyma enhancement (T(1), T(2) signal) and physiologic response (duodenal filling, pancreas duct response) to secretin. ePFT was categorized based on previously published data (normal peak bicarbonate >80 mEq/l). Referent values were calculated for MRCP and sMRCP using secretin ePFT as gold standard.
A total of 69 patients were identified (mean age 43.5 +/- 12; 65.2% female). 28 (40.6%) patients had abnormal ePFT based on their peak bicarbonate level. The mean bicarbonate values in the abnormal PFT and normal PFT groups were 59 +/- 13.9 and 95.3 +/- 12.6 mEq/l, respectively. Peak bicarbonate decreased with severity of chronic pancreatitis on MRCP (p = 0.0016). There was fair agreement of MRCP and ePFT (kappa 0.335 [0.113, 0.557]). The pre-stimulation pancreas duct changes reported were found to be the only predictor of abnormal pancreas function (p = 0.002). The post-stimulation findings of duodenal filling (p = 0.47), T(2)enhancement (p = 0.21) or change in pancreas duct caliber (p = 0.3) reported did not improve MRCP agreement with ePFT. Overall diagnostic accuracy, sensitivity and specificity were 70, 85 and 46%, respectively, for MRCP reports using ePFT as the gold standard.
Pancreas ductal features described on routine MRCP reports correlate with abnormal pancreas function. Current MRCP reports should be standardized to include all radiologic information available in hopes of predicting early chronic pancreatitis.
许多来自学术中心的出版物表明,磁共振胰胆管成像(MRCP)可诊断早期慢性胰腺炎(CP)并评估胰腺分泌储备/功能。然而,这些研究中报告的严格综合解读方法和定量分泌动力学在临床实践中并未常规测量。因此,常规 MRCP 报告在临床环境中的实用性尚不清楚。
对因腹痛而在三级中心接受 MRCP 和内镜胰腺功能检查(ePFT)评估慢性胰腺炎的患者进行横断面研究。
将 MRCP 和 sMRCP 报告与胰腺功能参考标准测试进行比较,以诊断慢性胰腺炎。
源人群:在三级转诊中心的胰腺诊所就诊的患者。回顾 MRCP 和 sMRCP 报告以记录胰腺导管(扩张、侧支变化)、实质增强(T1、T2 信号)和促胰液素的生理反应(十二指肠充盈、胰腺导管反应)。ePFT 根据先前发表的数据进行分类(正常峰值碳酸氢盐>80 mEq/l)。使用促胰液素 ePFT 作为金标准,计算 MRCP 和 sMRCP 的参考值。
共确定了 69 名患者(平均年龄 43.5 +/- 12;65.2%为女性)。根据碳酸氢盐峰值水平,28 名(40.6%)患者的 ePFT 异常。异常 PFT 和正常 PFT 组的平均碳酸氢盐值分别为 59 +/- 13.9 和 95.3 +/- 12.6 mEq/l。MRCP 上的碳酸氢盐峰值随慢性胰腺炎的严重程度而降低(p = 0.0016)。MRCP 和 ePFT 的一致性中等(kappa 0.335 [0.113, 0.557])。报告的刺激前胰腺导管变化是胰腺功能异常的唯一预测因素(p = 0.002)。刺激后的十二指肠充盈(p = 0.47)、T2 增强(p = 0.21)或胰腺导管直径变化(p = 0.3)等发现并不能提高 MRCP 与 ePFT 的一致性。使用 ePFT 作为金标准时,MRCP 报告的整体诊断准确性、敏感性和特异性分别为 70%、85%和 46%。
常规 MRCP 报告中描述的胰腺导管特征与胰腺功能异常相关。目前的 MRCP 报告应标准化,以包括所有可用的放射学信息,以期预测早期慢性胰腺炎。